Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Bladder Cancer, January 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 339 articles: HTML format

Single Articles

1. YANG CY, Ho SC, Chiu YW, Weng YH, et al
   Risk of death from bladder cancer in relation to long-term exposure to fine particulate air pollution in Taiwan.
   J Toxicol Environ Health A. 2026 Jan 2:1-10. doi: 10.1080/15287394.2025.2611423.
   Abstract
   
   
2. YAMAMOTO H, Oura S
   Possible Differentiation Between Recurrent Lymph Nodes of Bladder Cancer and Malignant Lymphoma on Ultrasound: A Case Report.
   Cureus. 2025;17:e98260.
   Abstract
   
   
3. SIKDER RK, Ellithi M, Uzzo RN, Weader DJ, et al
   Editor's Note: Differential Effects of Clinically Relevant N- versus C-Terminal Truncating CDKN1A Mutations on Cisplatin Sensitivity in Bladder Cancer.
   Mol Cancer Res. 2026;24:84.
   Abstract
   
   
4. ANWAR I, Pandith AA, Rasool SUA, Manzoor U, et al
   Promoter hypermethylation drives a paradoxical up regulation of hTERT with prognostic implications in bladder cancer.
   Urol Oncol. 2025 Dec 31:110963. doi: 10.1016/j.urolonc.2025.
   Abstract
   
   
5. SORIA F, Liedberg F, Stahl E, Dominguez-Escrig JL, et al
   Perioperative and Oncological Outcomes of Distal Ureterectomy for Upper Tract Urothelial Carcinoma (UTUC): A Multicentre Study from the European Association of Urology Non-muscle-invasive Bladder Cancer/UTUC Guidelines Panels with a Focus on Survival
   Eur Urol Oncol. 2025 Dec 31:S2588-9311(25)00328.
   Abstract
   
   
6. LEE J, Jung H, Kim EG, Ahn J, et al
   Phenotypic discovery and therapeutic evaluation of an ITGA3B1-targeting antibody-drug conjugate for bladder cancer.
   Sci Adv. 2026;12:eady0041.
   Abstract
   
   
7. JURCZOK N, Dernbach G, Ebner B, Plage H, et al
   Multiregional Immune Profiling Reveals Prognostic Patterns in Bladder Cancer.
   Eur Urol Oncol. 2025 Dec 30:S2588-9311(25)00333.
   Abstract
   
   
8. BIDI S, Nerli RB, Rangrez S, Ghagane SC, et al
   Association of SLC14A1C/T Polymorphisms in Patients with Bladder Cancer in Comparison with Healthy Controls.
   South Asian J Cancer. 2025;14:810-814.
   Abstract
   
   
9. SPITZER A, Aupperle-Lellbach H, Spitzer M, Weidle S, et al
   DAXX and ATRX Expression in Canine Prostate and Bladder Cancer Identified by Immunohistochemistry-A Digital Quantitative Pilot Study.
   Vet Sci. 2025;12:1209.
   Abstract
   
   
10. WOLF I, Giess N, Roider C, Schultze-Seemann S, et al
    Exploring EGFR, Nectin-4, and TROP-2 as Therapeutic Targets for Bladder Cancer Photoimmunotherapy.
    Molecules. 2025;30:4802.
    Abstract
    
    
11. KAYER A, Ozen A, Dinleyici EC
    Urinary Microbiota Composition in Treatment-Naive Bladder Cancer: A Case-Control Study with Tumor Invasiveness Stratification.
    Medicina (Kaunas). 2025;61:2240.
    Abstract
    
    
12. SONG B, Lee H, Lee S, Hong SK, et al
    Preoperative serum albumin level is associated with postoperative short- and long-term renal function deterioration in patients who underwent radical cystectomy for bladder cancer.
    Investig Clin Urol. 2026;67:24-31.
    Abstract
    
    
13. CERRATO C, Pandolfo SD, Kraft P, Ko DSC, et al
    Opportunistic salpingectomy during radical cystectomy for bladder cancer: A systematic review of the literature.
    Asian J Urol. 2025;12:471-477.
    Abstract
    
    
14. ANIS O, Bar V, Zundelevich A, Anil SM, et al
    Targeting bladder cancer: Potent anti-cancer effects of cannabichromene and delta-9-tetrahydrocannabinol-rich Cannabis sativa strains.
    Asian J Urol. 2025;12:534-543.
    Abstract
    
    
15. LAYMON M, Elsawy AA, Elsorougy A, Hashem A, et al
    Clinically lymph node-positive urothelial bladder cancer treated with upfront radical cystectomy: Diagnostic accuracy of MRI and long-term oncologic outcomes.
    Asian J Urol. 2025;12:520-528.
    Abstract
    
    
16. SONG M, Ren H, Wang L, Zhou Y, et al
    Beyond VI-RADS Uncertainty: Leveraging Spatiotemporal DCE-MRI to Predict Bladder Cancer Muscle Invasion.
    Bioengineering (Basel). 2025;12:1338.
    Abstract
    
    
17. CIGLIOLA A, Maiorano BA, Dengur D, Tateo V, et al
    The Management of Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives.
    Cancers (Basel). 2025;17:4017.
    Abstract
    
    
18. PLAGE H, Biernath N, Furlano K, Weinberger S, et al
    Differential Androgen Receptor Expression Across Bladder Cancer Stages and Its Link to Poor Outcomes.
    Cancers (Basel). 2025;17:3990.
    Abstract
    
    
19. HOSHI S, Meguro S, Makabe S, Onagi A, et al
    Immunosuppressive Role of Integrin beta8 in Recurrence After Bacillus Calmette-Guerin (BCG) Therapy for Non-Muscle Invasive Bladder Cancer.
    Cancers (Basel). 2025;17:3964.
    Abstract
    
    
20. XIAO B, Zeng Q, Peng X, He Q, et al
    An interpretable machine learning model based on CT imaging for predicting lymphovascular invasion and survival in bladder urothelial carcinoma: a multicenter study.
    BMC Med Imaging. 2025;25:513.
    Abstract
    
    
21. LI C, Meng F, Lu C, Li A, et al
    A smart amphiphilic nanoplatform amplifies ROS-mediated immunogenic cell death to suppress bladder cancer growth and metastasis.
    J Nanobiotechnology. 2025 Dec 29. doi: 10.1186/s12951-025-03935.
    Abstract
    
    
22. YANG CW, Yen CH, Chien TM, Yu SY, et al
    Excavatolide E triggers oxidative stress-associated apoptosis and DNA damage to inhibit bladder cancer cell proliferation.
    Mol Biol Rep. 2025;53:234.
    Abstract
    
    
23. LI L, Ren F, Liu Z, Tian X, et al
    Urothelial carcinoma following kidney transplantation: a narrative review of Chinese insights and challenges from pathogenesis to precision diagnosis and treatment.
    Front Immunol. 2025;16:1668356.
    Abstract
    
    
24. HO PARK J, Lee H, Lee S, Hong SK, et al
    Effect of early detubularization on urethro-intestinal anastomosis during robot-assisted radical cystectomy and intracorporeal neobladder among bladder cancer patients.
    Front Oncol. 2025;15:1680595.
    Abstract
    
    
25. KANEMOTO S, Yamamoto S, Hino K, Tsuboi K, et al
    Multiple Bone Metastases From Non-Muscle Invasive Bladder Cancer Responding to Combination Therapy With Enfortumab Vedotin and Pembrolizumab: A Case Report.
    IJU Case Rep. 2025;9:e70119.
    Abstract
    
    
26. PENUNURI A, Greenberg E, Phillips J, Katims AB, et al
    The Emerging Role of B Cells and Tertiary Lymphoid Structures in Bladder Cancer.
    Curr Urol Rep. 2025;27:3.
    Abstract
    
    
27. XU M, Yue S, Chen Z, Li R, et al
    hsa-miR-145-3p defines a fibro-inflammatory bladder cancer subtype with distinct therapeutic vulnerabilities.
    Discov Oncol. 2025 Dec 28. doi: 10.1007/s12672-025-04355.
    Abstract
    
    
28. WANG Y, Xue H, Xu S, Qin Y, et al
    Network toxicology analysis of hair dye components and their association with breast and bladder cancers.
    Afr J Reprod Health. 2025;29:204-216.
    Abstract
    
    
29. AHMADI SP, Sadabadi F, Khoshbin B, Sheikhi Z, et al
    Serum PSA levels fluctuations in patients with non-muscle-invasive bladder cancer (NMIBC) undergoing BCG therapy: a prospective study.
    BMC Urol. 2025 Dec 28. doi: 10.1186/s12894-025-02006.
    Abstract
    
    
30. MOUSA MMA, Abou-Dobara MI, El-Zahed MM, El-Sherif ME, et al
    Molecular detection and ultrastructure characterization of some drug-resistant Gram-negative bacteria isolated from bladder cancer patients.
    BMC Microbiol. 2025 Dec 27. doi: 10.1186/s12866-025-04572.
    Abstract
    
    
31. ZHONG MY, Zou XC, Chen PH
    Explainable machine learning predicts overall survival in female bladder cancer patients after radical cystectomy.
    Discov Oncol. 2025 Dec 27. doi: 10.1007/s12672-025-04275.
    Abstract
    
    
32. ZHANG M, Chen C, Zeng X, Zhao Q, et al
    Application of computed diffusion-weighted imaging in vesical imaging reporting and data system assessment for bladder cancer.
    Abdom Radiol (NY). 2025 Dec 27. doi: 10.1007/s00261-025-05358.
    Abstract
    
    
33. TAN J, Wang Y, Huang J, Dong B, et al
    Exploration of the Prognostic Value of PANoptosis-Related Genes in Bladder Cancer.
    Am J Mens Health. 2025;19:15579883251404985.
    Abstract
    
    
34. HU Z, Zeng D, Zhao X, Luo Y, et al
    Global Disparities and Temporal Trends in Prostate, Bladder, and Kidney Cancer Burden Among Men: A Systematic Analysis of 204 Countries (1990-2021).
    Cancer Control. 2025;32:10732748251411011.
    Abstract
    
    
35. HUANG J, Chen D, Ji G, Ma J, et al
    ERO1A promotes the proliferation, migration and invasion of bladder cancer through ALOX5 mediated activation of JAK-STAT signaling pathway.
    J Transl Med. 2025;23:1427.
    Abstract
    
    
36. NAIR MS, Scarborough J, Reddy CA, Bommireddy AR, et al
    Trimodality Therapy for Bladder Cancer: A Single Institution Retrospective Analysis of Factors Associated With Outcomes for High-Risk Patients Undergoing Organ-Sparing Therapy.
    Clin Genitourin Cancer. 2025;24:102477.
    Abstract
    
    
37. OLUMOYIN K, El Naqa L, Rejniak K
    Learning Model Parameter Dynamics in a Combination Therapy for Bladder Cancer from Sparse Biological Data.
    ArXiv [Preprint]. 2025 Dec 17:arXiv:2512.15706.
    Abstract
    
    
38. HANLON T, D'Andrea VD, Stelter I, Bekele R, et al
    Orthotopic bladder cancer preclinical models: Comprehensive review and technique optimization.
    Bladder Cancer. 2025;11:23523735251409720.
    Abstract
    
    
39. XUE Z, Qie Y, Shen C, Wu Z, et al
    Urinary Tumor DNA to Identify Candidates for Repeat Transurethral Resection in Non-Muscle-Invasive Bladder Cancer.
    Cancer Sci. 2025 Dec 24. doi: 10.1111/cas.70311.
    Abstract
    
    
40. LV J, Li K, Zhou J, Yu R, et al
    Histone deacetylase HDAC7 restricts CD8 + T cell tumor infiltration and limits immunotherapy sensitivity in bladder cancer: reversal by pinocembrin.
    J Exp Clin Cancer Res. 2025;44:324.
    Abstract
    
    
41. ROESSLER N, Miszczyk M, Gontero P, Miyajima K, et al
    Assessing clinical complete response after neoadjuvant systemic therapy in muscle-invasive bladder cancer: a systematic review.
    World J Urol. 2025;44:65.
    Abstract
    
    
42. LIU S, Liu T, Yang C, Mou Z, et al
    Cytoskeletal protein KRT14 governs cisplatin resistance by modulating eIF4H-dependent ACOX2 translation and lipid metabolism in bladder cancer.
    Cell Death Dis. 2025 Dec 24. doi: 10.1038/s41419-025-08369.
    Abstract
    
    
43. LIU H, Jiang X, Wang T, Zhang G, et al
    Low-dose corticomedullary phase CT urography with artificial intelligence iterative reconstruction for bladder cancer evaluation.
    Br J Radiol. 2025 Dec 24:tqaf315. doi: 10.1093.
    Abstract
    
    
44. PEKER P
    Correspondence regarding "Epidemiology, treatment patterns and effectiveness of adherence to Bacillus Calmette-Guerin therapy in intermediate and high-risk non-muscle-invasive bladder cancer patients: a retrospective cohort analysis using German healt
    World J Urol. 2025;44:64.
    Abstract
    
    
45. VANTAGGIATO L, Frisenda M, Shaba E, Splendore C, et al
    Proteomic Profiling of Non-Muscle Invasive Bladder Cancer Reveals Stage-Specific Molecular Signatures and Prognostic Biomarkers.
    Proteomes. 2025;13:65.
    Abstract
    
    
46. SILVANI C, Santangelo A, Considine J, Tylecki A, et al
    Incarcerated Patients Present with More Advanced Bladder Cancer Stage: A Statewide Analysis.
    Urol Pract. 2025 Dec 24:101097UPJ0000000000000961.
    Abstract
    
    
47. CARROLL TF, Bardot JP, David J, Zucker M, et al
    Compliance with Intravesical BCG Therapy for Non-Muscle Invasive Bladder Cancer.
    Urol Pract. 2025 Dec 24:101097UPJ0000000000000962.
    Abstract
    
    
48. OZGUN G, Alexander A, Arbour G, Kollmannsberger C, et al
    Bladder Preservation in Muscle-Invasive Bladder Cancer: A Population-Based Analysis from British Columbia.
    Curr Oncol. 2025;32:699.
    Abstract
    
    
49. HU K, Ma X, Luo L, Li P, et al
    FGL1 as an Immune Checkpoint in the Immune Microenvironment of Bladder Cancer.
    J Immunother. 2025 Dec 26. doi: 10.1097/CJI.0000000000000595.
    Abstract
    
    
50. MIYAJIMA K, Matsukawa A, Yanagisawa T, Miszczyk M, et al
    Neoadjuvant Chemotherapy Prior to Trimodality Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Eur Urol Open Sci. 2025;83:54-63.
    Abstract
    
    
51. JALAL H, Kang SK, Alarid-Escudero F, Chrysanthopoulou SA, et al
    Bladder Cancer Burden in the USA: Population Scenarios for 2040.
    Eur Urol Open Sci. 2025;83:99-108.
    Abstract
    
    
52. ZHUANG J, Yu H, Cao Q, Bai R, et al
    Consolidative Radical Cystectomy Following Neoadjuvant Tislelizumab Plus Gemcitabine and Cisplatin in Clinically Lymph Node-positive Bladder Cancer: A Prospective Study.
    Eur Urol Open Sci. 2025;83:36-45.
    Abstract
    
    
53. XIANG J, Luo Y, Zhang B, Ke K, et al
    Molecular mechanisms and translational advances in bladder cancer: from driver genes to precision therapy.
    Front Oncol. 2025;15:1670574.
    Abstract
    
    
54. ZHANG J, Wang Y, Yan Q, Wang H, et al
    SWI/SNF complex alterations predict immunotherapy response in bladder cancer.
    Front Immunol. 2025;16:1708324.
    Abstract
    
    
55. HAN Y, Peng J, Yan W, Wu Z, et al
    FLLL31 Induces Apoptosis via the FOXO4/BCL6 Axis to Inhibit Bladder Cancer Progression.
    Hum Mutat. 2025;2025:5947612.
    Abstract
    
    
56. CHEN J, Fu Y, Zhang Z, Zhao J, et al
    Nanomaterial-Enhanced Immunotherapy: Advancing T-Cell-Based Treatments for Bladder Cancer.
    Int J Nanomedicine. 2025;20:15235-15275.
    Abstract
    
    
57. GONG J, Sun D, Zheng Y, Mao C, et al
    Dauricine Inhibits Macrophages M2 Polarization and Regulates the Progression and Ferroptosis via HCK/IDO1 in Urinary Bladder Cancer.
    Food Sci Nutr. 2025;13:e71341.
    Abstract
    
    
58. CHEN D, Li Z, Sui Y, Zeng Y, et al
    The efficacy and safety of interval and post-reTURBT intravesical therapy for bladder cancer.
    iScience. 2025;28:114152.
    Abstract
    
    
59. LI Q, Chen QF, Liao NQ
    Graph Neural Network-Based Multi-Scale Whole Slide Image Fusion for pT Staging of Muscle-Invasive Bladder Cancer.
    Cancer Sci. 2025 Dec 23. doi: 10.1111/cas.70292.
    Abstract
    
    
60. LI M, Liu T, Shi J, Zhou F, et al
    USP43 promotes gemcitabine resistance by regulating cholesterol homeostasis through E2F1 stabilization in bladder cancer.
    J Exp Clin Cancer Res. 2025 Dec 23. doi: 10.1186/s13046-025-03621.
    Abstract
    
    
61. ZHI L, Yuan L
    Alantolactone curbs the malignant progression of bladder cancer partly via the HSP90AB1/LRP5/beta-catenin axis.
    Mamm Genome. 2025;37:20.
    Abstract
    
    
62. GOUHIZOUN O, Pattou M, Guena F, Khaddad A, et al
    Diagnostic accuracy of [18F]-FDG-PET/CT for lymph node staging in bladder cancer prior to radical cystectomy.
    World J Urol. 2025;44:59.
    Abstract
    
    
63. D'ALESSIO I, Siloche D, Civilini E, Bissacco D, et al
    Aortic complications after treatment with bacillus Calmette-Guerin: a tertiary hospital experience and an update of the literature.
    J Cardiovasc Surg (Torino). 2025;66:532-542.
    Abstract
    
    
64. DONG W, Bi J, Liu H, Yan D, et al
    Correction: Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis.
    Mol Cancer. 2025;24:309.
    Abstract
    
    
65. WANG C, Li K, Wan S, Chen S, et al
    TPI1 enhances gemcitabine resistance in bladder cancer by promoting autophagy through activating Beclin-1.
    Cell Death Dis. 2025;16:923.
    Abstract
    
    
66. YANG H, Liu X, Nie J, Wu S, et al
    USP7 promotes chemotherapy resistance and DNA damage response through stabilizing and deubiquitinating KDM4A in bladder cancer.
    Cell Death Dis. 2025 Dec 23. doi: 10.1038/s41419-025-08297.
    Abstract
    
    
67. ZHAO X, Liu H, Wang C, Guo F, et al
    Development of a prognostic model related to mitochondria and programmed cell death-related genes in bladder cancer.
    Front Genet. 2025;16:1615167.
    Abstract
    
    
68. LING Z, He S, Li T, Zhang J, et al
    Stem Cell-Related Gene CALR as a Novel Prognostic Factor for Bladder Cancer: Implications for Immunotherapy.
    Hum Mutat. 2025;2025:5569005.
    Abstract
    
    
69. WENG R, Phung TAT, Bell R, Dyrskjot L, et al
    Long non-coding RNAs define favourable biology in high-risk non-muscle-invasive bladder cancer.
    BJUI Compass. 2025;6:e70131.
    Abstract
    
    
70. MARTEL A, Raue L, Avogbe PH, Raisch J, et al
    Urinary biomarkers in multicentric studies: Shaping the future of bladder cancer diagnosis and follow-up.
    BJUI Compass. 2025;6:e70124.
    Abstract
    
    
71. LI C, Lv G, Xiong Z, Wang Z, et al
    Ginsenoside Rh2 Suppresses the Fanconi Anemia Pathway by Inhibiting NF-kappaB-Mediated FANCL Transcription in Bladder Cancer.
    Dose Response. 2025;23:15593258251411761.
    Abstract
    
    
72. DI SPIRITO A, Zuccolotto G, Tosi A, Balkhi S, et al
    Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies.
    Front Cell Dev Biol. 2025;13:1719978.
    Abstract
    
    
73. WANG JM, Xie HY, Zhang FH, Shu X, et al
    Aberrant KIF26B expression promotes bladder cancer progression through driving NSUN2 nuclear localization.
    J Hematol Oncol. 2025;18:110.
    Abstract
    
    
74. JANENZ J, Leipe A, Urban N, Schaefer M, et al
    Activation of TRPV3 channels in bladder cancer cells stimulates ATP release.
    Mol Pharmacol. 2025;108:100096.
    Abstract
    
    
75. LI G, Tatarano S, Yoshino H, Saito S, et al
    Therapeutic strategies for MMAE-resistant bladder cancer through DPP4 inhibition.
    Mol Oncol. 2025 Dec 21. doi: 10.1002/1878-0261.70187.
    Abstract
    
    
76. JAZAYERI SB, DiNatale RG, Guske C, Harrs C, et al
    Bacillus Calmette-Guerin-exposed Non-muscle-invasive Bladder Cancer: Survival Benchmarks, Bladder-sparing Strategies, and Implications for Trial Design.
    Eur Urol Focus. 2025 Dec 19:S2405-4569(25)00367.
    Abstract
    
    
77. JIANG L, Ge W, Feng R, Ji L, et al
    Innovative AI model for bladder cancer diagnosis.
    Discov Oncol. 2025 Dec 20. doi: 10.1007/s12672-025-04278.
    Abstract
    
    
78. SHI C, Xu J, Chen Q, Gao X, et al
    Novel DNA methylation biomarkers in urine for non-invasive diagnosis of bladder urothelial carcinoma.
    Clin Epigenetics. 2025;17:204.
    Abstract
    
    
79. XU C, Ying W, He Y, Wu Y, et al
    Vitamin C enhances cisplatin sensitivity in bladder cancer via 5hmC-mediated epigenetic modulation of ATF4.
    Clin Epigenetics. 2025;17:203.
    Abstract
    
    
80. JIANG Y, Xu C, He W, Zhang C, et al
    First-line therapies analysis in advanced/metastatic urothelial carcinoma: prognostic insights in ADCs combined therapy with propensity score analysis and RNA-Seq.
    Int Immunopharmacol. 2026;169:116060.
    Abstract
    
    
81. MAIORANO BA, Cigliola A, Tateo V, Mercinelli C, et al
    Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study.
    ESMO Open. 2025;10:105862.
    Abstract
    
    
82. GALSKY MD, Gschwend JE, Milowsky MI, Schenker M, et al
    Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.
    Ann Oncol. 2026;37:69-78.
    Abstract
    
    
83. CAINI S, Cosma C, Aprea MC, Saieva C, et al
    Heavy metals levels in pre-diagnostic serum of nonsmokers with cancer of the lung, bladder and prostate, and paired individuals.
    Arch Environ Occup Health. 2025;80:303-307.
    Abstract
    
    
84. SHAMSEDDINE A, Abbas N, Temraz S, Al Darazi M, et al
    Tetra-modality bladder preservation with avelumab for muscle-invasive urothelial cancer: a phase II trial (TRIUMPH-B01).
    Future Oncol. 2025;21:3873-3884.
    Abstract
    
    
85. PANER GP, Al-Ahmadie H, Gaisa NT, Lopez-Beltran A, et al
    The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Glandular Lesions of the Urinary Bladder.
    Adv Anat Pathol. 2026;33:1-16.
    Abstract
    
    
86. WAI R, Sheahen B, Thomas B
    Severe itch from miliaria managed with propantheline: a case report.
    BMJ Support Palliat Care. 2025;16:85-87.
    Abstract
    
    
87. HARSANYI S, Novakova ZV, Neuschlova L, Galbavy S, et al
    Optimizing Ki-67 and E-Cadherin Thresholds for Improved Grade and Stage Classification in Urothelial Bladder Cancer.
    J Clin Med. 2026;15:338.
    Abstract
    
    
88. TRILLA-FUERTES L, Pedregosa-Barbas J, Garcia-Fernandez E, Zambrana F, et al
    Identification of a Muscle-Invasive Bladder Carcinoma Molecular Subtype of Poor Responders to Neoadjuvant Chemotherapy and High Expression of Targetable Biomarkers.
    Int J Mol Sci. 2026;27:476.
    Abstract
    
    
89. NAKAGAWA Y, Yamamoto C, Kawajiri H, Watanabe M, et al
    Whole Genome Sequencing of Clinical Mycobacterium bovis BCG in Disseminated Infection with Mycotic Aneurysm and ARDS After Intravesical Therapy: A Case Report.
    Int J Mol Sci. 2025;27:238.
    Abstract
    
    
90. JAIN M, Tivtikyan A, Kislyakov D, Rakhmatullin T, et al
    The Diagnostic Performance of a Four-Gene Digital Droplet PCR Panel for Urine Liquid Biopsy in Urothelial Bladder Cancer.
    Diagnostics (Basel). 2025;16:69.
    Abstract
    
    
91. JAROMIN M, Kutwin P, Konecki T, Popiela D, et al
    Inflammation Indices as Predictive Markers of Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2025;18:136.
    Abstract
    
    
92. WU Z, Zeng J, Feng L, Zhu X, et al
    Tumor-homing cerium nanozyme platform enables coordinated drug release and STING activation for bladder cancer treatment.
    J Nanobiotechnology. 2026 Jan 10. doi: 10.1186/s12951-025-03955.
    Abstract
    
    
93. ADMIRE K, Gegick S
    Transvascular endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) to confirm urothelial carcinoma metastasis to the pulmonary artery.
    BMJ Case Rep. 2026;19:e268157.
    Abstract
    
    
94. RAGHAVAN D
    Sad But True: Inconsistent Care for Invasive Bladder Cancer.
    JCO Oncol Pract. 2026 Jan 9:OP2501254. doi: 10.1200/OP-25-01254.
    Abstract
    
    
95. YANG FH, Zhang W, Wang R, Mao S, et al
    Pseudomonas aeruginosa exacerbates bladder cancer progression by activating cancer-driven immunosuppression.
    Cancer Immunol Res. 2026 Jan 9. doi: 10.1158/2326-6066.CIR-25-0873.
    Abstract
    
    
96. GATELLIER L, Nakata K
    Age-standardized mortality-to-incidence ratio for bladder cancer in the world.
    Jpn J Clin Oncol. 2026;56:115-116.
    Abstract
    
    
97. ABOU CHAKRA M, Boormans JL, Hayne D, O'Donnell MA, et al
    Strategic sequencing of bladder-sparing therapies in the management of BCG-unresponsive non-muscle invasive bladder cancer.
    Ann Med. 2026;58:2612387.
    Abstract
    
    
98. SHAO YQ, Sheng DY, Guan YJ, Mi EX, et al
    [Mechanism of periplogenin in promoting Nrf2 degradation and inducing ferroptosis to inhibit bladder cancer].
    Zhongguo Zhong Yao Za Zhi. 2025;50:5790-5799.
    Abstract
    
    
99. REMMELINK MJ, El Awadly N, Arbeel-Weening B, Nadorp S, et al
    Correction: Impact of chemoradiotherapy for bladder cancer on pre-existing hydronephrosis and development of new hydronephrosis.
    Radiat Oncol. 2026;21:8.
    Abstract
    
    
100. XU D, Jacob JJ, Wieczorek K, Wang L, et al
     Modeling primary immunotherapy resistance in metastatic bladder cancer: a syngeneic, bioluminescent mouse model.
     Cancer Cell Int. 2026 Jan 8. doi: 10.1186/s12935-025-04117.
     Abstract
     
     
101. WANG H, Xiong Y, He T, He M, et al
     MXRA8, a key palmitoylation-related gene, promotes bladder cancer progression via remodeling tumor microenvironment and predicts poor prognosis.
     BMC Urol. 2026 Jan 8. doi: 10.1186/s12894-026-02046.
     Abstract
     
     
102. WANG J, Lu Q, Jiao P, Jian J, et al
     Machine Learning Integration Framework Constructs a Lactylation-Associated Gene Signature to Improve Prognosis in Bladder Cancer.
     Cancer Med. 2026;15:e71477.
     Abstract
     
     
103. HESSE M, Iltzsche M, Nahhas D, Thomas C, et al
     Type I-interferon beta induces a strong anti-tumour response in bladder cancer cells.
     J Cancer Res Clin Oncol. 2026;152:35.
     Abstract
     
     
104. JIN Z, Yang W, Peng Y, Ma L, et al
     HOXB4 Promotes Bladder Cancer Progression in Part Through Transcriptional Activation of Smoothened.
     FASEB J. 2026;40:e71388.
     Abstract
     
     
105. BAI R, Cai L, Jiang M, Wang C, et al
     Development and validation of MRI-based models to predict lymph node metastasis in bladder cancer: a multi-center study.
     Cancer Imaging. 2026 Jan 7. doi: 10.1186/s40644-025-00984.
     Abstract
     
     
106. DAI P, Chen L, Dong Z, Wang H, et al
     LncRNA FRMD6-AS2 inhibits the malignant progression of bladder cancer by targeting miR-1260a.
     World J Surg Oncol. 2026 Jan 7. doi: 10.1186/s12957-025-04171.
     Abstract
     
     
107. SINGH P, D'Rozario R, Chakraborty B, Meher S, et al
     Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer.
     Nat Commun. 2026 Jan 7. doi: 10.1038/s41467-025-68132.
     Abstract
     
     
108. SAOULI A, Contieri R, Quhal F, Hurle R, et al
     Efficacy and safety of active surveillance and chemoablation in the management of non-muscle invasive bladder cancer (NMIBC): Systematic review and pooled analysis by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma
     Actas Urol Esp (Engl Ed). 2026 Jan 5:501917. doi: 10.1016/j.acuroe.2026.501917.
     Abstract
     
     
109. LI X, Xie J, Song SJ, Ahlquist CSE, et al
     Sialic Acid Binding Liposome Nanoparticles for Targeted Bladder Cancer Therapy.
     ACS Biomater Sci Eng. 2026 Jan 7. doi: 10.1021/acsbiomaterials.5c01546.
     Abstract
     
     
110. CELLULAR LONGEVITY OMA
     RETRACTION: lncRNA OTUD6B-AS1 Exacerbates As(2)O(3)-Induced Oxidative Damage in Bladder Cancer via miR-6734-5p-Mediated Functional Inhibition of IDH2.
     Oxid Med Cell Longev. 2025;2025:9894089.
     Abstract
     
     
111. PIZZI JR, Adhikari I, Prakash P, Miyamoto H, et al
     Machine-learning-based determination of sex-related bladder cancer biomarkers.
     bioRxiv [Preprint]. 2025 Dec 23:2025.12.20.695175.
     Abstract
     
     
112. FALABELLA R, Porreca A, Foschi N, Salvaggio A, et al
     Robotic bladder diverticulectomy in patients with bladder diverticulum neoplasia: a single-center study.
     Arch Ital Urol Androl. 2025;97:14467.
     Abstract
     
     
113. BUZOIANU M, Buhas BA, Abou Chakra M, Ionutas E, et al
     A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania.
     Arch Ital Urol Androl. 2025;97:14596.
     Abstract
     
     
114. SHI G, Zhou X, Yang F, Wang T, et al
     Harnessing Ubiquitin-Proteasome System-Related Genes to Identify Subtypes of Bladder Cancer and Reveal Immune Landscape.
     Am J Mens Health. 2026;20:15579883251410519.
     Abstract
     
     
115. PATTOU M, Robert G, Gouhizoun O, Guena F, et al
     Persistent lymph node uptake on [18 F]-FDG PET-CT after neoadjuvant chemotherapy: a major predictive factor of disease-free survival in MIBC.
     World J Urol. 2026;44:77.
     Abstract
     
     
116. YUAN J, Yu S, Zheng J
     Epidemiological trends and future projections of bladder and kidney cancer burden in China, 1990-2041: an ecological study.
     Chin Clin Oncol. 2025;14:71.
     Abstract
     
     
117. FU Q, Yan F, Sun Z, Yao Z, et al
     Analysis of Urinary Continence, Complications, and Urodynamic Characteristics Following Orthotopic Ileocaecal Neobladder Reconstruction: A Preliminary Study on Safety and Feasibility.
     Arch Esp Urol. 2025;78:1493-1500.
     Abstract
     
     
118. ILKTAC A, Ersoz C, Kalkan S, Dogan B, et al
     Bleeding Risks in Urologic Surgery: A Prospective Analysis of Anticoagulant and Antiaggregant Use in Transurethral Resection of Prostate, Transurethral Resection of Bladder Tumour and Open Prostatectomy.
     Arch Esp Urol. 2025;78:1392-1400.
     Abstract
     
     
119. ST-LAURENT MP, Nikkola J, Tomiyama E, Black PC, et al
     Advances in the management of localized bladder cancers.
     Nat Rev Clin Oncol. 2026 Jan 5. doi: 10.1038/s41571-025-01104.
     Abstract
     
     
120. ROESSLER N, Maiorano BA, Miszczyk M, Miyajima K, et al
     First-line treatments for BCG-naive non-muscle invasive bladder cancer: a systematic review and meta-analysis.
     World J Urol. 2026;44:76.
     Abstract
     
     
121. 
     [Clinical pathological expert consensus on HER2 immunohistochemical testing in urothelial carcinoma(2026 version)].
     Zhonghua Bing Li Xue Za Zhi. 2026;55:7-15.
     Abstract
     
     
122. HE K, Lin C, Wang H, Wu H, et al
     The circ-GLG1/miR-346/KCNJ9 axis drives malignant progression of bladder cancer by modulating KCNJ9 expression.
     Exp Cell Res. 2026;455:114885.
     Abstract
     
     
123. MINATO A, Jojima K, Watanabe S, Sugita Y, et al
     Recurrence of Low-risk Non-muscle-invasive Bladder Cancer in Patients Who Did Not Receive Immediate Intravesical Chemotherapy.
     Cancer Diagn Progn. 2026;6:135-143.
     Abstract
     
     
124. ORAKZAI FK, Mirza W, Khan ME, Iqbal H, et al
     Robot-assisted versus open radical cystectomy with extracorporeal urinary diversion for bladder cancer: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials with subgroup analyses by orthotopic neobladder utilisation.
     J Robot Surg. 2026;20:151.
     Abstract
     
     
125. CHIANG Y, Tsai YC, Wang CC, Hsueh FJ, et al
     High-CD14-expressing urothelial cancer cells foster a neutrophil-rich tumor microenvironment that increases the risk of radiation-promoted distant metastasis.
     J Biomed Sci. 2026;33:2.
     Abstract
     
     
126. MAY M, Wolff I, Brookman-May S, Burger M, et al
     Re: Paramananthan Mariappan, Jasmin Hart-Brooke, Rebecca Sparks, Tanya Lord-McKenzie. Bladder EpiCheck Triggered Photodynamic Diagnosis Biopsies Detect High-grade Bladder Cancer Recurrences Missed by White Light Cystoscopy. Eur Urol Oncol. In press. h
     Eur Urol Oncol. 2026 Jan 3:S2588-9311(25)00341-4. doi: 10.1016/j.euo.2025.
     Abstract
     
     
127. SAITO M, Kakoi N, Izumi M, Aoki H, et al
     [A Case of Verrucous Carcinoma of the Bladder in a Patient with Cerebral Palsy].
     Hinyokika Kiyo. 2025;71:425-428.
     Abstract
     
     
128. WANG Y, Liu H, Wang T, Yang Y, et al
     GLRX5 is a prognostic marker in bladder cancer and correlates with activation of cancer-associated fibroblasts in the tumor microenvironment.
     Exp Cell Res. 2026;455:114884.
     Abstract
     
     
129. GUO C, Zhou Y, Liu X, Gao K, et al
     Analysis of the care needs of family caregivers of patients with bladder cancer undergoing urostomy: a cross-sectional study.
     Sci Rep. 2026 Jan 3. doi: 10.1038/s41598-025-34339.
     Abstract
     
     
130. LI Y, Zhao B, Gao W, Wu Y, et al
     Correction: LDB2 is a novel diagnostic and prognostic biomarker and inhibits bladder cancer metastasis by activating p38 MAPK/ERK1/2/JNK signaling pathway.
     Clin Exp Med. 2026;26:62.
     Abstract
     
     
131. BASU M, Chatterjee A, Chakraborty B, Chatterjee E, et al
     Retraction Note: High nuclear expression of HIF1alpha, synergizing with inactivation of LIMD1 and VHL, portray worst prognosis among the bladder cancer patients: association with arsenic prevalence.
     J Cancer Res Clin Oncol. 2026;152:26.
     Abstract
     
     
132. STURDIVANT MS, Truong AS, Zhou M, Toomer ED, et al
     APOBEC3 promotes squamous differentiation via IL-1A/AP-1 signaling.
     Nat Commun. 2025;17:334.
     Abstract
     
     
133. LIU P, Zhang L, Zhou Q, Fu Z, et al
     STIM1 N-linked glycosylation promotes arsenic-induced malignant phenotype by activating SOCE in bladder epithelial cells.
     Chem Biol Interact. 2026;424:111866.
     Abstract
     
     
134. YE Y, Chen Q, Huang Z, Huang Q, et al
     Preferred surgical strategies for bladder diverticular carcinoma.
     Sci Rep. 2025;16:917.
     Abstract
     
     
135. PEREIRA JA, Vieira-Brito D, Ferreira AM, Marques R, et al
     Hyperthermic vs normothermic mitomycin C for intermediate-risk NMIBC: a real-world retrospective cohort study.
     Arch Ital Urol Androl. 2025;97:14167.
     Abstract
     
     
136. YU EM, Linville L, Hwang MW, Kim Y, et al
     Harnessing genomic profiling for improved urothelial cancer outcomes.
     Expert Rev Anticancer Ther. 2026;26:93-104.
     Abstract
     
     
137. ZHANG T, Zhang X, Qian L, Hu C, et al
     Molecular and immune characteristics of neuroendocrine bladder carcinoma - Implications for diagnosis, prognosis, and therapy: A review.
     Biomol Biomed. 2025;26:711-719.
     Abstract
     
     
138. DIANA P, Gallioli A, Uleri A, Mas L, et al
     Attendings versus supervised residents: Educational results and future perspective in transurethral resection of bladder tumors.
     Actas Urol Esp (Engl Ed). 2026;50:501830.
     Abstract
     
     
139. CHENG AV, Bardell J, Sangoi AR
     Collision of Presumed Primary Urinary Bladder Malignant Melanoma and Invasive Urothelial Carcinoma: A Case Report.
     Int J Surg Pathol. 2026;34:201-206.
     Abstract
     
     
140. HISANAGA E, Sano T, Yokoo H
     Four Metachronous Cancers: Mutation Profiling Can Be Used to Distinguish Multiple Primary Cancers from Metastases.
     Intern Med. 2026;65:183-186.
     Abstract
     
     
141. KAYAR K, Dogan MB, Karabay E
     A Rare Presentation of Alveolar Soft Part Sarcoma in the Bladder.
     Int J Surg Pathol. 2026;34:158-161.
     Abstract
     
     
142. KASUKAWA S, Kametaka H, Makino H, Fukada T, et al
     [A Case of Pelvic Abscess Treated with Transperineal Drainage for Lower Gastrointestinal Perforation in Terminal Cancer].
     Gan To Kagaku Ryoho. 2025;52:1189-1191.
     Abstract
     
     
143. HATAKEYAMA T, Maeda T, Ide S
     [A Case of Synchronous Primary Cancers of the Rectum and Bladder].
     Gan To Kagaku Ryoho. 2025;52:1129-1130.
     Abstract
     
     
144. SALZANO G, Digiacomo A, Dello Stritto G, Orsini A, et al
     Artificial intelligence in bladder cancer management: a narrative review of diagnostic and surgical advances and current limitations.
     Expert Rev Anticancer Ther. 2026 Jan 16. doi: 10.1080/14737140.2026.2619018.
     Abstract
     
     
145. CHENG YT, Lu KH, Hong SY, Chen CH, et al
     Particulate matter 2.5 promotes bladder cancer cell migration and invasion through the crosstalk between integrin-mediated MAPK/ERK and Wnt/beta-catenin pathways.
     Part Fibre Toxicol. 2026 Jan 16. doi: 10.1186/s12989-025-00656.
     Abstract
     
     
146. YANG J, Li X, Xie H, Guo J, et al
     From mechanisms to therapy: the role of tertiary lymphoid structures in bladder cancer.
     World J Surg Oncol. 2026 Jan 17. doi: 10.1186/s12957-026-04196.
     Abstract
     
     
147. KHAN JS, Lonergan PE, McLoughlin LC
     Adherence to Bacille Calmette-Guerin protocol in the management of non-muscle invasive bladder cancer at St James's Hospital.
     Ir J Med Sci. 2026 Jan 17. doi: 10.1007/s11845-025-04260.
     Abstract
     
     
148. HAJIME T, Shiota M, Fukuchi G, Mutaguchi J, et al
     Tumor Laterality Predicts Pelvic Lymph Node Metastasis Patterns in Bladder Cancer.
     Ann Surg Oncol. 2026 Jan 16. doi: 10.1245/s10434-026-19088.
     Abstract
     
     
149. SASAKI Y, Izumi K, Fukuta K, Kadoriku F, et al
     Robot-Assisted Radical Cystectomy in the Very Elderly: A Propensity Score-Matched Comparison of Outcomes Between Patients Aged >/= 85 Versus 75-84 Years.
     Geriatr Gerontol Int. 2026;26:e70346.
     Abstract
     
     
150. MARAMI S, Tavakoli MH, Pashaki AS, Nikzad S, et al
     Computational analysis of the impact of urine volume on magnetic nanoparticle hyperthermia in the treatment of non-muscle-invasive bladder cancer.
     Eur J Pharm Biopharm. 2026 Jan 14:114992. doi: 10.1016/j.ejpb.2026.114992.
     Abstract
     
     
151. DYRSKJOT L, Birkenkamp-Demtroder K, Nordentoft I, Strandgaard T, et al
     ctDNA-Guided Immunotherapy following Radical Cystectomy for Muscle-Invasive Bladder Cancer: Results from the TOMBOLA Trial.
     Ann Oncol. 2026 Jan 14:S0923-7534(26)00011-6. doi: 10.1016/j.annonc.2025.
     Abstract
     
     
152. ZHANG Q, Zhang B, Niu J, Sun S, et al
     POSTN+ cancer-associated fibroblasts promote bladder cancer progression via angiogenesis and immune modulation: an analysis based on single-cell Transcriptomics.
     Integr Biol (Camb). 2026;18:zyag001.
     Abstract
     
     
153. KAWAI T, Miki J, Taoka R, Saito R, et al
     Age-stratified outcomes of radical cystectomy for muscle-invasive bladder cancer: a nationwide multicenter study of 1867 patients in Japan.
     Jpn J Clin Oncol. 2026 Jan 16:hyaf218. doi: 10.1093.
     Abstract
     
     
154. LAERT J, Lupi Manso N, Franca de Santana T, Santos PO, et al
     Pitfalls and Limitations of the Vesical Imaging-Reporting and Data System (VI-RADS): Challenges in the Multiparametric Magnetic Resonance Imaging (mpMRI) Assessment of Bladder Cancer.
     Cureus. 2025;17:e99197.
     Abstract
     
     
155. OKA R, Goto Y, Mikami K, Kato H, et al
     Renal Granuloma Distinct From the Renal Pelvis Following Bacillus Calmette-Guerin Treatment for Bladder Cancer: A Case Report.
     IJU Case Rep. 2026;9:e70141.
     Abstract
     
     
156. DAI Y, Zhang X, Lin Q, Gu X, et al
     Best evidence summary on gastrointestinal function recovery after radical cystectomy for bladder cancer.
     Asia Pac J Oncol Nurs. 2025;13:100824.
     Abstract
     
     
157. REYNARD M, Grobet-Jeandin E, Windisch O, Sebe P, et al
     [Urology. Quality of life and safety : the new promises].
     Rev Med Suisse. 2026;22:79-82.
     Abstract
     
     
158. ZHANG J, Zheng L, Yu Z, Chen Y, et al
     Single-cell and Bulk RNA-Seq Analyses Reveal TOMM7-mediated Multi-cell Death Mechanisms Driving Muscle-invasive Bladder Cancer Progression.
     Recent Pat Anticancer Drug Discov. 2026.
     Abstract
     
     
159. FULORIA NK, Narain K, Biswas A, Gnanam P, et al
     Tissue polypeptide antigen as a non-invasive bladder Cancer biomarker.
     Clin Chim Acta. 2026 Jan 13:120843. doi: 10.1016/j.cca.2026.120843.
     Abstract
     
     
160. CONTIERI R, Mollica V, Shariat SF, Pradere B, et al
     Comment to: ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guerin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC).
     Ann Oncol. 2026 Jan 13:S0923-7534(26)00012-8. doi: 10.1016/j.annonc.2026.
     Abstract
     
     
161. SQUIRES P, Coutinho F, Tepsick JG, Rogiers A, et al
     Real-world treatment patterns, recurrence, and overall survival of patients with muscle-invasive bladder cancer undergoing radical cystectomy in U.S. oncology practice.
     Urol Oncol. 2026;44:110982.
     Abstract
     
     
162. ILKI FY, Bulbul E, Topcu YK, Cinar O, et al
     Comparison of intravesical Bacillus Calmette-Guerin and chemohyperthermia with mitomycin C in with high-risk non-muscle-invasive bladder cancer: a critical assesment focusing on the quality of life and adverse events.
     BMC Urol. 2026 Jan 14. doi: 10.1186/s12894-025-02040.
     Abstract
     
     
163. AL-SATTAR H, Ding H, Okoli O, Okoli S, et al
     A multi-modal approach for decision making in bladder cancer.
     Nat Rev Urol. 2026 Jan 14. doi: 10.1038/s41585-025-01122.
     Abstract
     
     
164. MARIAPPAN P, Hart-Brooke J, Sparks R, Lord-McKenzie T, et al
     Reply to Matthias May, Ingmar Wolff, Sabine Brookman-May, and Maximilian Burger's Letter to the Editor re: Paramananthan Mariappan, Jasmin Hart-Brooke, Rebecca Sparks, Tanya Lord-McKenzie. Bladder EpiCheck Triggered Photodynamic Diagnosis Biopsies Det
     Eur Urol Oncol. 2026 Jan 13:S2588-9311(25)00344.
     Abstract
     
     
165. ZHU M, Liu Y, Jia Y, Ren L, et al
     Jujuboside A induces bladder cancer cell apoptosis by inhibiting ATP1A2-mediated mitochondrial energy metabolism regulation.
     Cancer Biol Ther. 2026;27:2615418.
     Abstract
     
     
166. CAO N, Cheng F
     TSTA3 promotes the malignant progression of bladder cancer by regulating LAMP2 and MAPK signaling pathway-mediated epithelial-mesenchymal transition.
     Genes Genomics. 2026 Jan 14. doi: 10.1007/s13258-025-01724.
     Abstract
     
     
167. ARON S, Meagher M, Azari S, Baker B, et al
     Beyond Sterility: the Urinary Microbiome in Bladder Cancer Carcinogenesis and Treatment.
     Curr Urol Rep. 2026;27:8.
     Abstract
     
     
168. DENIAUD C, Mesnard B, Bobet S, Perrouin-Verbe MA, et al
     Morbi-mortality of robot-assisted radical cystectomy for bladder carcinoma by urinary diversion type.
     J Robot Surg. 2026;20:173.
     Abstract
     
     
169. GE T, Liu F, Cai M, Wu J, et al
     Using transcriptomics and molecular docking to uncover the pharmacological targets and its associated biological mechanisms of paeoniflorigenone in treating bladder cancer.
     Discov Oncol. 2026 Jan 14. doi: 10.1007/s12672-026-04404.
     Abstract
     
     
170. CHEN J, Liu X, Ren R, Yi R, et al
     Single-cell and immune-context integration identifies basement-membrane/metastasis signatures that sharpen bladder-cancer diagnosis and prognosis.
     Discov Oncol. 2026 Jan 14. doi: 10.1007/s12672-026-04440.
     Abstract
     
     
171. DENIAUD C, Mesnard B, Bobet S, Perrouin-Verbe MA, et al
     Oncologic outcomes of robot-assisted radical cystectomy for bladder carcinoma by urinary diversion type.
     World J Urol. 2026;44:93.
     Abstract
     
     
172. WU X, Zhou Y, Chen J, Zhang H, et al
     A high-throughput photothermal aptasensing platform using MnO(2)@CuS nanoprobes for noninvasive detection of bladder cancer cells in simulated liquid biopsy.
     Mikrochim Acta. 2026;193:88.
     Abstract
     
     
173. INUI S, Ito S, Ueda T, Shiraishi T, et al
     Efficacy and safety of cryoablation procedures using mouse models of bladder cancer.
     Sci Rep. 2026 Jan 13. doi: 10.1038/s41598-026-35571.
     Abstract
     
     
174. DADABHOY A, Doshi C, Zahir M, Ladi-Seyedian S, et al
     Alopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case series.
     Urol Oncol. 2026;44:110984.
     Abstract
     
     
175. MAN X, Zhang X, Dong A, He J, et al
     Isolated Vaginal Recurrence of Urothelial Bladder Cancer on FDG PET/CT.
     Clin Nucl Med. 2026 Jan 6. doi: 10.1097/RLU.0000000000006294.
     Abstract
     
     
176. MJAESS G, Quackels T, Fantoni JC, Tricard T, et al
     Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004).
     World J Urol. 2026;44:90.
     Abstract
     
     
177. PEREZ-LONDONO A, Kaul S, Fleishman A, Korets R, et al
     Repeat transurethral resection and contemporary oncologic outcomes among patients with non-muscle invasive urothelial carcinoma of the bladder.
     World J Urol. 2026;44:91.
     Abstract
     
     
178. ZHOU H, Peng S, Ling Z, Cai J, et al
     Multi-omics analysis identifies BUB1B as a cell cycle-related driver of bladder cancer progression.
     World J Surg Oncol. 2026 Jan 12. doi: 10.1186/s12957-025-04175.
     Abstract
     
     
179. AYDIN ME, Aykac A, Kaya C, Sungur M, et al
     Comparative analysis of EAU, AUA, and NCCN guidelines for the management of non-muscle invasive bladder cancer.
     BMC Urol. 2026 Jan 12. doi: 10.1186/s12894-026-02045.
     Abstract
     
     
180. REGNIER S, Gabriel PE, Ouzaid I, Moschini M, et al
     Second-look transurethral resection in high-grade Ta non-muscle invasive bladder cancer.
     World J Urol. 2026;44:84.
     Abstract
     
     
181. SUNGUR U, Bitkin A, Eksi M, Polat H, et al
     Machine learning methods for predicting early recurrence in Ta stage bladder cancer and comparison with conventional statistical methods.
     Minerva Urol Nephrol. 2026 Jan 12. doi: 10.23736/S2724-6051.25.06385.
     Abstract
     
     
182. ZHANG F, Yang Y, Zhang R, Hu H, et al
     Curcumol overcomes cisplatin resistance and rewires glycolysis-H3K9la-ORC6 axis to trigger ferroptosis in bladder cancer.
     Chin J Cancer Res. 2025;37:1034-1057.
     Abstract
     
     
183. 
     Expression of miR-149-3p inhibits proliferation, migration, and invasion of bladder cancer by targeting S100A4 [Retraction].
     Am J Cancer Res. 2025;15:5395.
     Abstract
     
     
184. HUANG H, Ye F, Liu T, Hong J, et al
     Nano-Immunotherapy Synergizing Ferroptosis and STING Activation in Metastatic Bladder Cancer.
     Cyborg Bionic Syst. 2026;7:0458.
     Abstract
     
     
185. DE ALMEIDA MF, Rosa BG, Delechiave D, Annequin LF, et al
     rBCG-LTAK63 Outperforms BCG in Bladder Cancer Immunotherapy: Dendritic and T Cell Coordination Drives Superior Tumor Control in a Mouse Model.
     Int J Biol Sci. 2026;22:713-730.
     Abstract
     
     
186. SCILIPOTI P, Zaurito P, Longoni M, Tremolada G, et al
     Real-world outcomes of bladder-sparing strategies for BCG-unresponsive non-muscle-invasive bladder cancer: a multicenter study.
     World J Urol. 2026;44:82.
     Abstract
     
     
187. CHEN L, Jin C, Guo E, Liu F, et al
     The Performance of MR Cytometry Imaging in Differentiating High- and Low-Grade Bladder Cancer.
     J Magn Reson Imaging. 2026 Jan 11. doi: 10.1002/jmri.70232.
     Abstract
     
     
188. MUMUNI AN
     Editorial for "The Performance of MR Cytometry Imaging in Differentiating High- and Low-Grade Bladder Cancer".
     J Magn Reson Imaging. 2026 Jan 11. doi: 10.1002/jmri.70238.
     Abstract
     
     
189. CHENG LH, Hsu CW, Yang PM, Liao TY, et al
     Chemotherapy resistance of urinary bladder cancer mediated by a Notch and Wnt co-regulatory module of stemness.
     Stem Cells. 2026 Jan 10:sxag002. doi: 10.1093.
     Abstract
     
     
190. SYNESI G, Lewis R, Kilburn L, Bliss J, et al
     Reviewing inclusivity of the UK bladder and head and neck oncology trial portfolio through eligibility criteria: a scoping review.
     Trials. 2026;27:19.
     Abstract
     
     
191. KAYRAKLIOGLU N, Zhang L, Cornelia Ding CK, Greenland NY, et al
     Correlation of lymphocytic infiltration and degree of pleomorphism with tumor mutation burden in high-grade urothelial carcinoma.
     Hum Pathol. 2026;167:106005.
     Abstract
     
     
192. FERNANDEZ O, Molina A, Anido-Herranz U, Alvarez C, et al
     Real-world data on avelumab in first-line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG-AVELUMAB RWD study.
     Clin Transl Oncol. 2026;28:254-264.
     Abstract
     
     
193. FERNANDEZ RODRIGUEZ P, Castillo Gazquez L, Tomas Alvarez S, Casals Seoane F, et al
     Abdominal BCGitis with hepatosplenic and lymphatic involvement following intravesical therapy: a rare complication.
     Rev Esp Enferm Dig. 2025;117:797-799.
     Abstract
     
     
194. PARK I, Lee JL, Yoon S, Shin SJ, et al
     A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTIMA; KCSG GU20-03).
     Cancer Res Treat. 2026;58:284-291.
     Abstract
     
     
195. MEZEPO G, Khene ZE, Boustani J, Kleinclauss F, et al
     Oncological Outcomes of Trimodal Therapy in Primary Versus Secondary Muscle-invasive Bladder Cancer: A Multicenter Retrospective Study.
     Eur Urol Oncol. 2026 Jan 22:S2588-9311(25)00343.
     Abstract
     
     
196. GABRIEL PE, Xylinas E
     The Future of Non-muscle-invasive Bladder Cancer: Towards a Molecular-Digital Paradigm for Personalized Management.
     Eur Urol Focus. 2026 Jan 22:S2405-4569(26)00004.
     Abstract
     
     
197. REIS LO
     Bladder Cancer Immunotherapy in 2025: ALBAN, CREST, POTOMAC, and the Winner Is BCG!
     Int Braz J Urol. 2026;52:e20259921.
     Abstract
     
     
198. SUGAWARA D, Hatakeyama K, Konno M, Tozawa T, et al
     Decision tree models combining Bi-parametric vesical imaging reporting and data system and apparent diffusion coefficient metrics for predicting muscle-invasive bladder cancer.
     Abdom Radiol (NY). 2026 Jan 23. doi: 10.1007/s00261-026-05389.
     Abstract
     
     
199. ZHAO Q, Gao S, Du Q, Liu Y, et al
     [Expression of Concern] Long non?coding RNA SNHG20 promotes bladder cancer via activating the Wnt/beta?catenin signalling pathway.
     Int J Mol Med. 2026;57:66.
     Abstract
     
     
200. KUO WT, Pan CC, Liu YW, Chow NH, et al
     Autophagy Plays a Suppressive Role in Bladder Tumor Formation in an Orthotopic Mouse Model and Bladder Cancer Patient Specimens.
     Kaohsiung J Med Sci. 2026 Jan 23:e70179. doi: 10.1002/kjm2.70179.
     Abstract
     
     
201. LIU L, Liang T, Huang G, Deng D, et al
     Electroacupuncture in Combination with Bevacizumab Hydrogel Provides a Therapeutic Strategy for Bladder Cancer.
     ACS Appl Mater Interfaces. 2026 Jan 22. doi: 10.1021/acsami.6c00404.
     Abstract
     
     
202. 
     Long-term impact of synchronous and metachronous bladder cancer on prognosis after radical nephroureterectomy for upper urinary tract urothelial carcinoma: results from a large population-based cohort in China: Erratum.
     Int J Surg. 2026;112:2201.
     Abstract
     
     
203. DYRSKJOT L
     ctDNA-guided treatment decisions in muscle-invasive bladder cancer.
     Nat Rev Urol. 2026 Jan 22. doi: 10.1038/s41585-026-01125.
     Abstract
     
     
204. HUANG Y, Chen C, Su M, Ye W, et al
     TMEM11 promotes cisplatin resistance by inhibiting BNIP3-mediated mitophagy in bladder cancer.
     Cancer Lett. 2026;641:218271.
     Abstract
     
     
205. DO NT, Nguyen Tung L, Nguyen Cong D, Do MT, et al
     Tumor Morphology as a Risk Factor for Muscle Invasiveness in Newly Diagnosed Bladder Cancer: A Stratified Analysis.
     Asian Pac J Cancer Prev. 2026;27:151-156.
     Abstract
     
     
206. STROJNY Z, Kanikowska A, Sikora W, Lewandowska M, et al
     First look at evaluation of serum angiopoietin-like 4 levels in bladder cancer: A pilot study.
     J Physiol Pharmacol. 2026;76:673-680.
     Abstract
     
     
207. NAGUMO Y, Ye X, Shi T, Mathis BJ, et al
     Revealing intra-group immunotherapy response heterogeneity in metastatic urothelial carcinoma through interpretable feature extraction and spectral clustering.
     Front Immunol. 2026;16:1629001.
     Abstract
     
     
208. NUMATA Y, Ito H, Tatenuma T, Noguchi G, et al
     [A CASE OF ACUTE EXACERBATION OF INTERSTITIAL PNEUMONIA AFTER ROBOT-ASSISTED TOTAL CYSTECTOMY].
     Nihon Hinyokika Gakkai Zasshi. 2025;116:37-40.
     Abstract
     
     
209. KURETAKE K, Minato A, Harada S, Fujimoto N, et al
     [CLINICAL OUTCOMES OF NEUROENDOCRINE CARCINOMA OF THE URINARY BLADDER].
     Nihon Hinyokika Gakkai Zasshi. 2025;116:10-16.
     Abstract
     
     
210. YAMADA R, Hayakawa N, Kikuchi E
     [PERIOPERATIVE INCIDENCE OF VENOUS THROMBOEMBOLISM IN BLADDER CANCER PATIENTS TREATED BY OPEN RADICAL CYSTECTOMY].
     Nihon Hinyokika Gakkai Zasshi. 2025;116:1-9.
     Abstract
     
     
211. HUSSEIN AA, Klugman Y, Carlson J, Bhat TA, et al
     Does the urinary microbiome reflect the bladder-cancer-associated microbiome? Characterizing the microbiome in urine and cancer tissue in bladder cancer.
     Urol Oncol. 2026;44:110978.
     Abstract
     
     
212. CALOUDAS AB, Haltom TM, Taylor JM
     "It's Killed My Sex Life": Veteran Bladder Cancer Survivors' Perspectives on Sexual Problems and Intimacy.
     Arch Sex Behav. 2026 Jan 21. doi: 10.1007/s10508-025-03364.
     Abstract
     
     
213. SONG S MSC, Yang W MSc, Gao C MD
     Comment on "The role of adjuvant chemotherapy after radical surgery in patients with lymph node-positive bladder cancer or locally advanced (pT3, pT4a) bladder cancer: a meta-analysis and systematic review".
     Int J Surg. 2026 Jan 20. doi: 10.1097/JS9.0000000000004892.
     Abstract
     
     
214. LI M, Liu X, Xue Y, Lu Y, et al
     Integrative bulk and single-cell transcriptomic analysis reveals COL1A2-driven ECM remodeling and focal adhesion signaling associated with the transition from non-muscle-invasive to muscle-invasive bladder cancer.
     Front Oncol. 2026;15:1716324.
     Abstract
     
     
215. YAN B, Hu W, Li Y, Feng T, et al
     Hyperthermic intravesical chemotherapy with gemcitabine versus Bacillus Calmette-Guerin in intermediate- and high-risk non-muscle-invasive bladder cancer.
     Front Oncol. 2026;15:1715762.
     Abstract
     
     
216. SONG F, Su S, Zhang X, Cao Y, et al
     Association between the red cell distribution width-to-albumin ratio and recurrence-free survival and overall survival in patients with non-muscle-invasive bladder cancer: a retrospective cohort study.
     Front Oncol. 2026;15:1710047.
     Abstract
     
     
217. REDDY N, Lau K, Naman J, Lu K, et al
     Killing cancer takes guts: lessons learned from the manipulation of gut microbiome and immunotherapy for the future of urothelial carcinoma.
     Oncoimmunology. 2026;15:2611458.
     Abstract
     
     
218. FAN D, Meng R, Han Y, Zhai Z, et al
     Conservative versus aggressive transurethral resection of bladder cancer for paraureteral bladder cancer: A comparison of postoperative ureteral stricture and cancer recurrence rates.
     Medicine (Baltimore). 2026;105:e47176.
     Abstract
     
     
219. CAI J, Jiao C, Xu Y, Zhang F, et al
     Polarity protein Par3 deficiency promotes metastasis of bladder cancer via interaction of Ppp1r12c.
     Biol Direct. 2026 Jan 20. doi: 10.1186/s13062-026-00727.
     Abstract
     
     
220. LI Y, Zhou Z, Liu J, Cheng Z, et al
     En bloc versus conventional transurethral resection for non-muscle-invasive bladder cancer: an expanded and updated systematic review and meta-analysis reconciling contemporary evidence on oncological, pathological, and safety outcomes.
     World J Surg Oncol. 2026 Jan 20. doi: 10.1186/s12957-025-04172.
     Abstract
     
     
221. JIANG M, Chen S, Ma H, Shi Y, et al
     Intratumoral and Peritumoral Fat CT?Based Radiomics for Predicting Recurrence Risk in Non-Muscle-Invasive Bladder Cancer: A Two-Center Study.
     Ann Surg Oncol. 2026 Jan 20. doi: 10.1245/s10434-025-18981.
     Abstract
     
     
222. HE W, Wen Y, Qin H
     LncRNA NPSR1-AS1 affects the malignant biological behavior of bladder cancer through miR-199a-3p and the clinical value of urine-derived lncRNA NPSR1-AS1.
     Urol Oncol. 2026;44:110980.
     Abstract
     
     
223. SHANG LL, Hu TL, Xiong S, Xu S, et al
     Design and synthesis of dual-activity biphenyl inhibitors against SARS-CoV-2 and bladder cancer.
     Eur J Med Chem. 2026;306:118581.
     Abstract
     
     
224. STUART J, Zhuleku E, Mevius A, Squires P, et al
     Characteristics, Treatment Patterns, and Outcomes of Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Analysis of Health Insurance Claims Data in Germany.
     Oncol Ther. 2026 Jan 20. doi: 10.1007/s40487-025-00413.
     Abstract
     
     
225. HAYAKAWA N, Kikuchi E
     [Current Landscape of Sequential Treatment Strategy in Metastatic Urothelial Carcinoma].
     Gan To Kagaku Ryoho. 2026;53:21-24.
     Abstract
     
     
226. KITA Y
     [Current Development of Perioperative Immune Checkpoint Inhibitor Therapy for Muscle-Invasive Bladder Cancer].
     Gan To Kagaku Ryoho. 2026;53:16-20.
     Abstract
     
     
227. SHIGEHISA R, Fukata S, Inoue K
     [Evolving Pharmacotherapy for Bladder Cancer-From Non-Muscle-Invasive to Metastatic Disease-Development of Novel Therapies for BCG-Unresponsive NMIBC].
     Gan To Kagaku Ryoho. 2026;53:10-15.
     Abstract
     
     
228. KAWAHARA T
     [Recent Progress in Novel Therapies for Non-Muscle Invasive Bladder Cancer].
     Gan To Kagaku Ryoho. 2026;53:7-9.
     Abstract
     
     
229. ST-LAURENT MP, Nikkola J, Tomiyama E, Black PC, et al
     Author Correction: Advances in the management of localized bladder cancers.
     Nat Rev Clin Oncol. 2026 Jan 19. doi: 10.1038/s41571-026-01121.
     Abstract
     
     
230. LONGONI M, Falkenbach F, Marmiroli A, Le QC, et al
     Development and external validation of a nomogram predicting cancer-specific mortality-free survival after trimodal therapy in muscle-invasive bladder cancer.
     World J Urol. 2026;44:111.
     Abstract
     
     
231. ZHAO Z, Zhao Z, Bu X, Wang M, et al
     Added value of synthetic MRI in refining biparametric MRI VI-RADS for predicting muscle-invasive bladder cancer.
     Abdom Radiol (NY). 2026 Jan 19. doi: 10.1007/s00261-025-05365.
     Abstract
     
     
232. EL MJABBER R, Alami R, Aouzah F, Bezzari W, et al
     Integrated Boost vs. Sequential Scheme in Volumetric Modulated Arc Therapy (VMAT) for Trimodal Bladder Cancer Therapy: A Comparative Study.
     Cureus. 2025;17:e99438.
     Abstract
     
     
233. KAUFMANN E, Aeppli S, Affentranger A, Arnold N, et al
     Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer.
     Bladder Cancer. 2026;12:23523735251410823.
     Abstract
     
     
234. WU J, Jin S, Bai Q, Wang H, et al
     Noninvasive Early Detection and Recurrence Monitoring for Non-Muscle-Invasive Bladder Cancer via Urine Tumor DNA: A Prospective Clinical Study.
     MedComm (2020). 2026;7:e70592.
     Abstract
     
     
235. YAMANAKA R, Miura K, Yamasaki N, Ogata S, et al
     Angiotensin II type 1 receptor signaling promotes bladder cancer progression and its inhibition by Losartan.
     Hypertens Res. 2026 Jan 19. doi: 10.1038/s41440-025-02535.
     Abstract
     
     
236. LU L, Cheng H, Liu S, Tao Y, et al
     TAK-901 targeted inhibition of EGFR activates transcription factor FOXO causing cell cycle arrest and apoptosis in bladder cancer.
     Mol Cancer Ther. 2026 Jan 19. doi: 10.1158/1535-7163.MCT-25-0507.
     Abstract
     
     
237. XU T, Wang K, Chen Y, Yu Y, et al
     Adjuvant bacillus Calmette-Guerin (BCG) immunotherapy versus BCG combined with disitamab vedotin in BCG-naive high-risk non-muscle invasive bladder cancer with HER2 expression: A real-world study.
     Int Immunopharmacol. 2026;172:116186.
     Abstract
     
     
238. RICHTERS A, Franken MD, Meijer RP, van der Heijden AG, et al
     Treatments and survival outcomes of patients with synchronous and metachronous metastatic bladder cancer: A population-based nationwide cohort study.
     Cancer Treat Res Commun. 2026;46:101099.
     Abstract
     
     
239. MOHAMED T, Bani Irshid BA, Elhashamy H, Deameh MG, et al
     Optimal duration of perioperative antibiotics in radical cystectomy and urinary diversion: a systematic review and meta-analysis.
     Langenbecks Arch Surg. 2026;411:58.
     Abstract
     
     
240. RICCIARDI G, Tralongo P, Pierconti F, Zuccala V, et al
     Urothelial Carcinoma In Situ: Advances in Diagnosis and Management.
     Clin Genitourin Cancer. 2026;24:102478.
     Abstract
     
     
241. KURIAN M, Mamtani R, Elghawy O, Nimgaonkar V, et al
     Real-World Enfortumab Vedotin +/- Pembrolizumab Treatment-Based Toxicities and Associations With Survival in Advanced Urothelial Carcinoma.
     Clin Genitourin Cancer. 2026;24:102474.
     Abstract
     
     
242. WENG C, Deng H, Yang Z, Zeng X, et al
     Regulation of drug resistance in bladder urothelial carcinoma by tumor aerobic glycolysis.
     J Transl Med. 2025;24:85.
     Abstract
     
     
243. CARVALHO D, Pinto S, Sarmento B
     Modeling the human bladder tissue using three dimensional in vitro approaches as a tool for drug screening platforms.
     Acta Biomater. 2026;210:296-313.
     Abstract
     
     
244. REVERDY T, Izarn F, Allignet B, Roubaud G, et al
     Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study.
     Clin Genitourin Cancer. 2026;24:102465.
     Abstract
     
     
245. COCA MEMBRIBES S, Szabados B, Powles T
     Towards biomarker-driven therapies for urothelial carcinoma.
     Nat Rev Clin Oncol. 2026;23:92-106.
     Abstract
     
     
246. LITT HK, Mamtani R, Chow RD
     Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction.
     Urol Oncol. 2026;44:118.
     Abstract
     
     
247. DOGRA S, Lee J, Siriruchatanon M, Gu Z, et al
     Incidental Bladder Lesions on Prostate Multiparametric MRI: Prevalence and Factors Associated with Bladder Carcinoma.
     Acad Radiol. 2026;33:472-481.
     Abstract
     
     
248. CHEVILLE JC, Orme JJ, Gupta S, Lucien-Matteoni F, et al
     Defining NECTIN4 Amplification and Protein Expression in Urothelial Carcinoma and Histologic Subtypes.
     Mod Pathol. 2026;39:100928.
     Abstract
     
     
249. MAREI A, Hohls M, Touloumtzidis A, Katoh M, et al
     Metastasis of an urothelial carcinoma as rare cause of an AV-graft dysfunction in a transgender patient.
     J Vasc Access. 2026;27:326-331.
     Abstract
     
     
250. RAHMADI R, Mudhia Arisa Putri U, Herman H, Rachman W, et al
     Case Report: Radical urethrectomy with partial cystectomy and bladder outlet reconstruction in giant female urethral adenocarcinoma infiltrating the bladder: A rare case report.
     F1000Res. 2026;14:741.
     Abstract
     
     
251. ZHANG X, Zong R, Sun Y, Chen N, et al
     The FN1-ITGB4 Axis Drives Acquired Chemoresistance in Bladder Cancer by Activating FAK Signaling.
     Oncol Res. 2026;34:21.
     Abstract
     
     
252. FENG R, Zhang J, Tao Y, Hou J, et al
     Preoperative inflammation-based immune prognostic nomogram in bladder cancer: a multicenter study.
     Front Oncol. 2026;15:1644747.
     Abstract
     
     
253. CHEN ST, Chang KS, Hou CP, Lin WY, et al
     WISP1 is the stromal-secreting oncoprotein via paracrine downregulation of NDRG1, KAI1, and Maspin in human bladder cancer cells.
     Transl Oncol. 2026;65:102680.
     Abstract
     
     
254. NEBIOGLU A, Basaranoglu M, Bozlu M, Tek M, et al
     Effects of dutasteride with Bacillus Calmette-Guerin therapy on recurrence, progression, metastasis, and survival in non-muscle invasive bladder cancer: a retrospective single-center study.
     BMC Urol. 2026 Jan 28. doi: 10.1186/s12894-026-02059.
     Abstract
     
     
255. LU Q, Guo J, Xu Y, Cui Y, et al
     RAD54B as a biomarker for prognosis and immunotherapy response in bladder cancer.
     Discov Oncol. 2026 Jan 28. doi: 10.1007/s12672-026-04514.
     Abstract
     
     
256. MARCQ G, Dahm P, Maisch P
     En-bloc resection: Evidence and uncertainty Re: Comparative effectiveness of en-bloc resection techniques vs. conventional transurethral resection for non-muscle-invasive bladder cancer: A systematic review and meta-analysis.
     Can Urol Assoc J. 2026;20:E80-E81.
     Abstract
     
     
257. SHIH YC, Wu CY, Huang SW, Tsai CY, et al
     Multimodal Large Language Models for Cystoscopic Image Interpretation and Bladder Lesion Classification: Comparative Study.
     J Med Internet Res. 2026;28:e87193.
     Abstract
     
     
258. SHI WY, Liu KJ, Esfahani MS, Mach KE, et al
     Field-effect-informed urine liquid biopsy for bladder cancer.
     Cell. 2026 Jan 27:S0092-8674(25)01503-X. doi: 10.1016/j.cell.2025.
     Abstract
     
     
259. SCHERRER M, Brunaiova L, Furrer M, John H, et al
     How safe is teaching radical cystectomy? : Results from the prospective Swiss society of urology database.
     World J Urol. 2026;44:133.
     Abstract
     
     
260. HE Y, Xie J, Zhong S, Zhan C, et al
     A Deep Learning-Generated Mixed Tumor-Stroma Ratio for Prognostic Stratification and Multi-omics Profiling in Bladder Cancer.
     Research (Wash D C). 2026;9:1053.
     Abstract
     
     
261. HU H, Huang J, Ma L, Zhang S, et al
     Hexaminolevulinate blue light cystoscopy improves bladder cancer detection in comparison to white light cystoscopy: a prospective, comparative, within-patient controlled multicenter phase III bridging study in China.
     Front Urol. 2026;5:1713128.
     Abstract
     
     
262. PAN S, Cui W, Lin J, Wang Z, et al
     The infection-microbiome-immunity axis in bladder cancer: mechanistic insights and therapeutic perspectives.
     Front Immunol. 2026;16:1716230.
     Abstract
     
     
263. FRYD ND, Albertsen N, Bernth-Andersen S, Ernst A, et al
     The GreenBladder Study: Early Detection of Bladder Cancer in Greenland Using a Urinary Biomarker.
     J Clin Med. 2026;15:761.
     Abstract
     
     
264. KLATTE T, Bold F, Dengler J, de Martino M, et al
     Trends in the Management of Bladder Cancer with Emphasis on Frailty: A Nationwide Analysis of More Than 49,000 Patients from a German Hospital Network.
     Life (Basel). 2026;16:169.
     Abstract
     
     
265. ALQAISI O, Tai P, Storme G
     Specialized Nursing-Led Interventions for Bladder Cancer Management: A Scoping Review of Evidence and Clinical Outcomes.
     Medicina (Kaunas). 2026;62:185.
     Abstract
     
     
266. NEBIOGLU A, Turhan A, Basaranoglu M, Bozlu M, et al
     Prognostic Significance of Hemogram Parameters in Non-Muscle Invasive Bladder Cancer: A Comprehensive Retrospective Analysis.
     Medicina (Kaunas). 2025;62:51.
     Abstract
     
     
267. COJOCARU I, Guliciuc M, Cojocaru E, Serban C, et al
     A Review of the Latest Evidence on Prognostic Factors in Locally Advanced and Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
     Medicina (Kaunas). 2025;62:46.
     Abstract
     
     
268. JIANG H, Chen Y, Zeng X, Yang R, et al
     The Role of Natural Compounds in Bladder Urothelial Carcinoma Treatment.
     Int J Mol Sci. 2026;27:596.
     Abstract
     
     
269. MOHAMED AA, AbdulAzeem Y, Almudaifer AI, ZainEldin H, et al
     Explainable Computational Imaging for Precision Oncology: An Interpretable Deep Learning Framework for Bladder Cancer Histopathology Diagnosis.
     Bioengineering (Basel). 2025;13:4.
     Abstract
     
     
270. NAN Z, Zhao W, Li S, Yue C, et al
     Unequal Progress in Early-Onset Bladder Cancer Control: Global Trends, Socioeconomic Disparities, and Policy Efficiency from 1990 to 2021.
     Healthcare (Basel). 2026;14:193.
     Abstract
     
     
271. CERIA F, Muhammad G, Del Giudice F, Ibrahim Y, et al
     Unveiling the Female Factor: Gender-Based Differences in Outcomes and Survival Following Radical Cystectomy for Bladder Cancer.
     Cancers (Basel). 2026;18:308.
     Abstract
     
     
272. PACKIAM VT, Ghodoussipour S, Konety BR, Ahmadi H, et al
     Impact of Computational Histology AI Biomarkers on Clinical Management Decisions in Non-Muscle Invasive Bladder Cancer: A Multi-Center Real-World Study.
     Cancers (Basel). 2026;18:249.
     Abstract
     
     
273. PITOUT A, Mazeaud C, Blondeau A, Salleron J, et al
     Sarcopenia Predicts Mortality in Bladder Cancer with Neoadjuvant Chemotherapy: A Multicenter Study.
     Cancers (Basel). 2026;18:222.
     Abstract
     
     
274. SANDHU K, Hopkins DT, Newton M, Sathianathen N, et al
     Oligometastatic Bladder Cancer: Current Definitions, Diagnostic Challenges, and Evolving Therapeutic Strategies.
     Cancers (Basel). 2026;18:189.
     Abstract
     
     
275. PIRES I, Files R
     Silent Threats: A Narrative Review of Urinary Bladder Cancer in Dogs and Cats-Epidemiology and Risk Factors.
     Animals (Basel). 2026;16:217.
     Abstract
     
     
276. MIKI J, Kimura S, Urabe F, Atsuta M, et al
     Optimizing pelvic lymph node dissection in bladder cancer: obturator focus, pN1 prognosis, and sentinel node feasibility.
     Int J Clin Oncol. 2026 Jan 27. doi: 10.1007/s10147-026-02969.
     Abstract
     
     
277. SHEN L, Yu C, Wu Y, Chen H, et al
     NFIB suppresses cell migration, invasion and EMT of bladder cancer through the PI3K-AKT signaling pathway.
     Cytotechnology. 2026;78:33.
     Abstract
     
     
278. QIU M, Zhang S, Liang J, Chen G, et al
     Prolyl 4-Hydroxylase Beta Peptide Promotes Invasion, Migration, and Epithelial-Mesenchymal Transition through Activation of the Claudin-1/ AMPK/TGF-beta1 Pathway in Bladder Cancer Cells.
     Protein Pept Lett. 2026 Jan 22. doi: 10.2174/0109298665418763251124051527.
     Abstract
     
     
279. ZENG D, Liu B, Deng F, Wang Y, et al
     Multidimensional liquid biopsy in bladder cancer: advances in circulating tumor cells, circulating tumor DNA, exosomes, and metabolomics.
     Oncologist. 2026;31:oyaf409.
     Abstract
     
     
280. SILVA TA, Viana LG, Carvalho VM, Bertolla RP, et al
     Proteomic Profiling of Non-Muscle Invasive Bladder Cancer Reveals Potential Biomarkers for Recurrence and Progression Risk.
     J Proteome Res. 2026 Jan 26. doi: 10.1021/acs.jproteome.5c00486.
     Abstract
     
     
281. WANG X, Preston A, Aning J, Loizou M, et al
     Early Detection of Bladder Cancer Using Advanced Feature Engineering and Swarm Intelligence Optimization on EHRs.
     IEEE Trans Biomed Eng. 2026;PP.
     Abstract
     
     
282. KARKEET RM, Sayed-Ahmed MM, Ghaly S, Farouk M, et al
     Comprehensive Evaluation of Bacillus Calmette-Guerin therapy in Non-muscle invasive bladder cancer Egyptian patients: a retrospective cohort study.
     J Egypt Natl Canc Inst. 2026;38:2.
     Abstract
     
     
283. ZHANG WW, Qu HR, Du XS, Sun SJ, et al
     SREBP2-RAB11A-ZDHHC20 axis orchestrates FGFR3 palmitoylation and membrane retention to drive bladder cancer progression.
     Cell Oncol (Dordr). 2026;49:30.
     Abstract
     
     
284. NAPPI A, Crocetto F, Conforti P, Sagliocchi S, et al
     Cell-free RNA profiling uncovers non-canonical circulating D2 transcript elevation in Bladder Cancer plasma.
     J Liq Biopsy. 2026;11:100454.
     Abstract
     
     
285. WANG P, Deng J, Wu S
     Modeling and validation of serum miR-18a and miR-122 levels as predictors of recurrence after laparoscopic radical cystectomy procedure for bladder cancer based on nomogram model.
     Front Oncol. 2026;15:1579873.
     Abstract
     
     
286. HARMON JF, Santos E, Johnson-Pais TL, Leach RJ, et al
     Association of CCL2/CCR2 gene polymorphisms and bladder cancer risk in a hispanic-rich US population.
     Bladder Cancer. 2026;12:23523735261417401.
     Abstract
     
     
287. SU X, Yu H, Zhang M, Zeng K, et al
     A novel prognostic model based on epithelial cell progression genes identifies OAS1 as a suppressor of bladder cancer aggressiveness.
     Front Mol Biosci. 2026;12:1716130.
     Abstract
     
     
288. YUAN Z, Situ M, Ye Y, Zhang J, et al
     Dissecting the role of KLF5: from tumor progression to immune interactions with emphasis on glioma and bladder cancer.
     Front Immunol. 2026;16:1730356.
     Abstract
     
     
289. CHAN CC, Lee MJ, Su J, Su JJ, et al
     Exploring Pembrolizumab-Induced IM3OS in a Patient With Bladder Cancer.
     Pharmacol Res Perspect. 2026;14:e70212.
     Abstract
     
     
290. CHEN Y, Lao M, Shen M, Wang Z, et al
     TMIGD2 in Bladder Cancer: A Bioinformatics and Experimental Approach to Understanding its Prognostic and Therapeutic Potential.
     Curr Top Med Chem. 2026 Jan 15. doi: 10.2174/0115680266414071251126071447.
     Abstract
     
     
291. CHEN Y, Zhu H, Lao M, Ding G, et al
     Exploring ZPLD1 as a Prognostic Indicator and Therapeutic Target in Bladder Cancer.
     Curr Med Chem. 2026 Jan 15. doi: 10.2174/0109298673413898251122184011.
     Abstract
     
     
292. FANG Q, You C, Xiao X, Yang W, et al
     Targeting the WWP2-ASPP2 axis overcomes cisplatin resistance by inhibiting the mevalonate pathway in TP53-mutant bladder cancer.
     Int J Biol Macromol. 2026;343.
     Abstract
     
     
293. LUTY M, Szydlak R, Pabijan J, Ovreeide IH, et al
     Identification of glycosylation-related changes in migratory and mechanical properties of bladder cancer cells.
     Biosens Bioelectron. 2026;298:118410.
     Abstract
     
     
294. CHEN M, Zheng L, Huang D, Wang S, et al
     RBM15/IGF2BP3 promotes immune escape in bladder cancer by enhancing m6A modification of PFKFB4.
     Int J Biol Macromol. 2026 Jan 22:150142. doi: 10.1016/j.ijbiomac.2026.150142.
     Abstract
     
     
295. CHEN Q, Wu R, Zhang C, Xie J, et al
     Efficacy and safety of tislelizumab plus intravesical chemotherapy in recurrent high-risk non-muscle-invasive bladder cancer: A retrospective single-center real-world study.
     Urol Oncol. 2026;44:110988.
     Abstract
     
     
296. KLUTH M, Plage H, Furlano K, Hofbauer S, et al
     PTEN Deletions Are Associated With Tumor Progression But Unrelated to Patient Prognosis in Muscle-Invasive Urothelial Bladder Carcinomas: A Large Multi-Center Validation Study on 2710 Urothelial Bladder Carcinomas.
     Genes Chromosomes Cancer. 2026;65:e70105.
     Abstract
     
     
297. CHEN WW, Wu B, Wen X
     Causal association between socioeconomic disparities and tumors of the urinary system: A Mendelian randomization study.
     Medicine (Baltimore). 2026;105:e47216.
     Abstract
     
     
298. WANG Y, Bhandary P, Moore JH, Li X, et al
     Integrative microRNA and transcriptome analysis reveals sex-specific molecular divergence in human bladder cancer.
     Biol Sex Differ. 2026 Jan 23. doi: 10.1186/s13293-026-00829.
     Abstract
     
     
299. BENTSEN L, Lund-Jacobsen T, Jakobsen CB, Larsen FM, et al
     Shared Decision-Making in Curative Uro-Oncology: A Systematic Review.
     Semin Oncol Nurs. 2026;42:152116.
     Abstract
     
     
300. SRIVASTAVA A, Trivedi S, Kumar U, Singh Y, et al
     Quality of life and cost-effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG-naive non-muscle-invasive bladder cancer.
     BJU Int. 2025 Dec 23. doi: 10.1111/bju.70126.
     Abstract
     
     
301. MENNES J, Akand M, Benijts R, Baekelandt L, et al
     Prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: does it really have an effect on oncological outcomes?
     BJU Int. 2025 Dec 23. doi: 10.1111/bju.70096.
     Abstract
     
     
302. PELLEGRINO F, de Angelis M, Scilipoti P, Longoni M, et al
     Temporal trends and clinical determinants of urinary diversion after radical cystectomy.
     BJU Int. 2026;137:323-331.
     Abstract
     
     
303. SUBIELA JD, de la Parra I, Taborda J, Medina AA, et al
     Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy.
     BJU Int. 2026;137:270-281.
     Abstract
     
     
304. SILVANI C, Santangelo A, Considine J, Tylecki A, et al
     Area deprivation and cancer-specific mortality in non-muscle-invasive bladder cancer: a statewide analysis.
     BJU Int. 2026 Jan 20. doi: 10.1111/bju.70151.
     Abstract
     
     
305. ABOU CHAKRA M, McElree IM, Mott SL, O'Donnell MA, et al
     Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer.
     BJU Int. 2026 Jan 19. doi: 10.1111/bju.70149.
     Abstract
     
     
306. BHATTACHARYA R, Kponee-Shovein K, Gao Y, Song Y, et al
     Event-free survival and complete response rate as surrogate endpoints for overall survival in high-risk non-muscle-invasive bladder cancer: A meta-analysis of bacillus Calmette-Guerin-naive or -remote cases.
     Cancer. 2026;132:e70220.
     Abstract
     
     
307. CHEVRIER S, Richard C, Adotevi O, Ayyoub M, et al
     Circulating transcriptome analysis finds gene signatures and immune cell activation and abundance predict response to immunotherapy in bladder cancer.
     Clin Cancer Res. 2026 Jan 13. doi: 10.1158/1078-0432.CCR-25-2306.
     Abstract
     
     
308. EPSTEIN IB, Odogiyon A, Berg S, Otani Y, et al
     ctDNA dynamics and recurrence patterns after organ-sparing trimodality therapy for bladder cancer.
     Clin Cancer Res. 2026 Jan 26. doi: 10.1158/1078-0432.CCR-25-3712.
     Abstract
     
     
309. SCILIPOTI P, Zaurito P, Longoni M, Colecchia M, et al
     Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guerin (BCG) in BCG-naive High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials.
     Eur Urol. 2025 Dec 31:S0302-2838(25)04877-8. doi: 10.1016/j.eururo.2025.
     Abstract
     
     
310. GALLAGHER K, MacLennan S, Bhatt N, Clement K, et al
     RESECT: A Randomised Controlled Trial of Audit and Feedback in Non-muscle-invasive Bladder Cancer Surgery.
     Eur Urol. 2025 Dec 10:S0302-2838(25)04736-0. doi: 10.1016/j.eururo.2025.09.4174.
     Abstract
     
     
311. FILHO AM, Briganti A, Jemal A, Bray F, et al
     Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.
     Eur Urol. 2025 Dec 19:S0302-2838(25)04864-X. doi: 10.1016/j.eururo.2025.
     Abstract
     
     
312. HERR H
     Re: Oscar Buisan, Pol Servian, Sonia Pedreno-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial. Eur Urol.
     Eur Urol. 2026 Jan 12:S0302-2838(25)04897-3. doi: 10.1016/j.eururo.2025.
     Abstract
     
     
313. ROVIELLO G, Vascotto IA, Antonuzzo L
     Re: ctDNA-guided Adjuvant Atezolizumab in Muscle-invasive Bladder Cancer.
     Eur Urol. 2026 Jan 12:S0302-2838(26)00008-4. doi: 10.1016/j.eururo.2026.
     Abstract
     
     
314. KITAMURA H, Tsukamoto T, Kakehi Y, Mizusawa J, et al
     Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial.
     Eur Urol. 2026 Jan 21:S0302-2838(26)00014-X. doi: 10.1016/j.eururo.2026.
     Abstract
     
     
315. GARMAN TS, Kates MR
     Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2
     Eur Urol. 2026 Jan 19:S0302-2838(26)00016-3. doi: 10.1016/j.eururo.2026.
     Abstract
     
     
316. PICHLER R, Subiela JD, Scilipoti P, Rehder P, et al
     Regional Node-positive Bladder Cancer: Therapeutic Decisions Based on Trial Results in Perioperative and Advanced Disease Settings.
     Eur Urol. 2026 Jan 19:S0302-2838(26)00019-9. doi: 10.1016/j.eururo.2026.
     Abstract
     
     
317. NAGUMO Y, Kimura T, Ishikawa H, Sekino Y, et al
     Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial.
     Eur Urol. 2026 Jan 17:S0302-2838(25)04872-9. doi: 10.1016/j.eururo.2025.
     Abstract
     
     
318. CABRERA C, Buisan O, Servian P
     Reply to the Harry Herr's Letter to the Editor re: Oscar Buisan, Pol Servian, Sonia Pedreno-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Canc
     Eur Urol. 2026 Jan 23:S0302-2838(26)00018-7. doi: 10.1016/j.eururo.2026.
     Abstract
     
     
319. NIEDERSUESS-BEKE D, Mayrhofer K, Krauter J, Franke J, et al
     Enfortumab vedotin plus pembrolizumab in treatment-naive metastatic urothelial carcinoma patients: An Austrian real-world analysis.
     Int J Cancer. 2026;158:1654-1665.
     Abstract
     
     
320. DU J, Shen H, Zeng T, Liu W, et al
     Targeted therapies for urothelial carcinoma: From FGFR inhibitors to next?generation antibody-drug conjugates (Review).
     Int J Oncol. 2026;68:28.
     Abstract
     
     
321. TAOKA R, Fukuhara H, Miyake M, Kobayashi K, et al
     Predictive Factors for Gastrointestinal and Hepatic Adverse Events During 5-Aminolevulinic Acid-Guided Photodynamic Diagnosis in Bladder Cancer: Exploratory Analysis of the Phase III SPP2C102 Trial.
     Int J Urol. 2025 Dec 25. doi: 10.1111/iju.70328.
     Abstract
     
     
322. FIORENTINO V
     Editorial Comment to "Prediction of Postoperative Intravesical Recurrence Using Urine DNA Monitoring in Non-Muscular-Invasive Urothelial Bladder Cancer".
     Int J Urol. 2025 Dec 25. doi: 10.1111/iju.70332.
     Abstract
     
     
323. CHEN W, Yoshida S, Ikeda R, Yoshimura R, et al
     Oligometastatic Prostate and Bladder Cancer: An Integrative Narrative Review.
     Int J Urol. 2025 Dec 24. doi: 10.1111/iju.70324.
     Abstract
     
     
324. IWASAWA T, Tsujino T, Tsukahara S, Fukushima H, et al
     Translational Advances in Urothelial Carcinoma: From Bench to Bedside.
     Int J Urol. 2026;33:e70341.
     Abstract
     
     
325. HIRATA H
     Editorial Comment on Oligometastatic Prostate and Bladder Cancer: An Integrative Narrative Review.
     Int J Urol. 2026;33:e70343.
     Abstract
     
     
326. FUJITA N
     Editorial Comments to "Real-World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical Bacillus Calmette-Guerin (BCG) Therapy in BCG-Naive or -Unresponsive Non-Muscle-Invasive Bladder Cancer".
     Int J Urol. 2026;33:e70358.
     Abstract
     
     
327. SOMA T, Tanaka H, Nakamura Y, Numao N, et al
     Clinical Features and Risk Factors of Enfortumab Vedotin-Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study (YUSHIMA Study).
     Int J Urol. 2026;33:e70329.
     Abstract
     
     
328. ZAHIR M, Moghadam FS, Ladi-Seyedian SS, Ghoreifi A, et al
     Can Urinary Diversion Type Affect Postoperative Complications Following Radical Cystectomy in Female Patients?
     Int J Urol. 2026;33:e70330.
     Abstract
     
     
329. SHIMIZU S, Osawa T, Sato M, Yamada S, et al
     Validation of the 7-Item Quality of Life Disease-Specific Impact Scale in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Cross-Sectional Study.
     Int J Urol. 2026;33:e70364.
     Abstract
     
     
330. FUKUTA K, Sasaki Y, Daizumoto K, Izumi K, et al
     Prognostic Significance of Achieving the Radical Cystectomy-Pentafecta After Neoadjuvant Chemotherapy and Robot-Assisted Radical Cystectomy.
     Int J Urol. 2026;33:e70283.
     Abstract
     
     
331. CHAI Y, Zhou Y, Peng H, Jiang Y, et al
     Comparative efficacy of hyperthermic chemotherapy and BCG instillation in non-muscle invasive bladder cancer: a systematic review and meta-analysis.
     Int Urol Nephrol. 2026 Jan 11. doi: 10.1007/s11255-026-05008.
     Abstract
     
     
332. OZDEN SB, Bulbul E, Ilki Y, Vural A, et al
     Effect of frailty status and histopathological features on upstaging of non-muscle-invasive bladder cancer: a critical analysis based on machine learning.
     Int Urol Nephrol. 2026 Jan 26. doi: 10.1007/s11255-026-05021.
     Abstract
     
     
333. AYKAC A, Kaya C, Sungur M, Aydin ME, et al
     Holmium laser en?bloc vs bipolar and conventional monopolar TURBT for non?muscle?invasive bladder cancer.
     Int Urol Nephrol. 2026 Jan 24. doi: 10.1007/s11255-026-05023.
     Abstract
     
     
334. PAN XW, Li L, Huang Y, Huang H, et al
     [Corrigendum] Icaritin acts synergistically with epirubicin to suppress bladder cancer growth through inhibition of autophagy.
     Oncol Rep. 2026;55:51.
     Abstract
     
     
335. TJIAMAN MP, Zaidan MZ, Ausath ZF, Putri AT, et al
     Quality of Life and Postoperative Complications of Single- or Bilateral-stoma Cutaneous Ureterostomy Compared to Ileal Conduit After Radical Cystectomy: A Systematic Review and Meta-analysis.
     Urology. 2026;207:287-292.
     Abstract
     
     
336. HEARD JR, Pagano I, Rosser C, Tan WS, et al
     Hematuria Cancer Risk Score in Combination With Oncuria-Detect for Patients Undergoing Evaluation for Hematuria.
     Urology. 2026;207:178-183.
     Abstract
     
     
337. YANG IN, Liang CA, Wu CC, Xu QS, et al
     Comprehensive surveillance of MicroRNA to discriminate between muscle-invasive and non-muscle-invasive urothelial carcinoma based on noninvasive urinary small RNA sequencing in Taiwanese patients.
     BMC Cancer. 2025;25:1900.
     Abstract
     
     
338. RAO XP, Zou XC, Yu ZJ, Yuan YY, et al
     Interpretable machine learning using CT radiomics predicts pathological upgrading after secondary resection in non-muscle-invasive bladder cancer.
     BMC Cancer. 2026 Jan 19. doi: 10.1186/s12885-026-15554.
     Abstract
     
     
339. DARJI S, Qu F, Henager M, Prasad A, et al
     Optimizing mRNA delivery with targeted elastin-like polypeptide-based LENN formulations: Insights into the endocytosis mechanism.
     Proc Natl Acad Sci U S A. 2026;123:e2502486122.
     Abstract